A Multi-Site, Open-Label, Trial of the Efficacy and Safety of Fixed-dose Elbasvir/Grazoprevir (EBR/GZR) in Brazilian Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 May 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Fibrosis; Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 May 2017 Planned End Date changed from 13 Oct 2018 to 12 Jan 2019.
- 23 May 2017 Planned primary completion date changed from 21 Jul 2018 to 12 Jan 2019.
- 23 May 2017 Planned initiation date changed from 16 Aug 2017 to 29 Nov 2017.